Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Patrick Grohs is active.

Publication


Featured researches published by Patrick Grohs.


Antimicrobial Agents and Chemotherapy | 2003

In Vitro Bactericidal Activities of Linezolid in Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic Acid, and Rifampin against Staphylococcus aureus

Patrick Grohs; Marie-Dominique Kitzis; Laurent Gutmann

ABSTRACT The in vitro activities of linezolid were determined alone and in combination with vancomycin, ciprofloxacin, gentamicin, fusidic acid, or rifampin against five methicillin-susceptible Staphylococcus aureus (MSSA) and five methicillin-resistant S. aureus (MRSA) strains. Similar responses were obtained against MSSA and MRSA. When combined with fusidic acid, gentamicin, or rifampin, linezolid prevented selection of resistant mutants but showed no synergy. When linezolid was combined with vancomycin and ciprofloxacin, a slight antagonism was observed. While the combination with linezolid may reduce the emergence of mutants resistant to the associated drugs, the absence of synergy, especially in the case of vancomycin and ciprofloxacin, does not argue in favor of such combinations.


Journal of Microbiological Methods | 2012

Robustness of two MALDI-TOF mass spectrometry systems for bacterial identification

Etienne Carbonnelle; Patrick Grohs; Hervé Jacquier; Nesrine Day; Sylvie Tenza; Alexandra Dewailly; Odile Vissouarn; Martin Rottman; Jean-Louis Herrmann; Isabelle Podglajen; Laurent Raskine

MALDI-TOF-MS systems (Microflex-Bruker Daltonics/BioTyper™ and Axima-Assurance-Shimadzu/SARAMIS-AnagnosTec) were assessed for bacterial identification. Focusing on bacteria difficult to identify routinely, 296 strains were identified by molecular biology techniques as gold standard. MALDI-TOF-MS identification provided correct results at genus and species level for 94.9%, 83.4% and 83.8%, 65.9% with Biotyper and Saramis respectively.


Journal of Clinical Microbiology | 2007

Relevance of Routine Use of the Anaerobic Blood Culture Bottle

Patrick Grohs; Jean-Luc Mainardi; Isabelle Podglajen; Xavier Hanras; Catherine Eckert; Annie Buu-Hoï; Emmanuelle Varon; Laurent Gutmann

ABSTRACT Using the BacT/Alert automated system, we conducted a 1-year retrospective study on blood cultures, focusing on the relevance of routine use of the anaerobic bottle. The rate of patients with positive blood cultures was 19.7%. Among these, 13.5% had a positive anaerobic bottle in the absence of any aerobic bottle, and 2/3 of these grew with nonobligate anaerobes. These patients were hospitalized in 20 out of 26 wards of the hospital group. For 65.4% of the monomicrobial-positive blood cultures growing Enterobacteriaceae, the anaerobic bottle detected growth earlier than the corresponding aerobic bottle. These data suggest that, in our institution, the use of an anaerobic bottle is still relevant.


Journal of Bacteriology | 2000

Vancomycin Resistance Is Associated with Serine-Containing Peptidoglycan in Enterococcus gallinarum

Patrick Grohs; Laurent Gutmann; Raymond Legrand; Bernard Schoot; Jean Luc Mainardi

In Enterococcus gallinarum SC1, a low-level vancomycin-resistant strain, only monomeric muropentapeptides with a C-terminal D-alanine were detected after growth without vancomycin. In contrast, in SC1 induced by vancomycin, as well as in AIB39, a constitutive vancomycin-resistant strain, monomeric and dimeric muropentapeptides with a C-terminal D-serine were detected.


Antimicrobial Agents and Chemotherapy | 2003

In Vitro Activities of Garenoxacin (BMS-284756) against Streptococcus pneumoniae, Viridans Group Streptococci, and Enterococcus faecalis Compared to Those of Six Other Quinolones

Patrick Grohs; Serge Houssaye; Agnès Aubert; Laurent Gutmann; Emmanuelle Varon

ABSTRACT The activity of garenoxacin, a new quinolone, was determined in comparison with other quinolones against different strains of S. pneumoniae, viridans group streptococci (VGS), and Enterococcus faecalis. Strains were quinolone-susceptible clinical isolates and quinolone-resistant strains with defined mechanisms of resistance obtained from either clinical isolates or derivatives of S. pneumoniae R6. Clinical quinolone-susceptible strains of S. pneumoniae, VGS and E. faecalis showed garenoxacin MICs within a range of 0.03 μg/ml to 0.25 μg/ml. Garenoxacin MICs increased two- to eightfold when one mutation was present in the ParC quinolone resistance-determining region (QRDR), fourfold when one mutation was present in the GyrA QRDR (S. pneumoniae), 8- to 64-fold when two or three mutations were associated in ParC and GyrA QRDR, and 2,048-fold when two mutations were present in both the GyrA and ParC QRDRs (Streptococcus pneumoniae). Increased active efflux had a moderate effect on garenoxacin MICs for S. pneumoniae and VGS. Against S. pneumoniae, garenoxacin behaved like moxifloxacin and sparfloxacin, being more affected by a single gyrA mutation than by a single parC mutation. Although garenoxacin was generally two- to fourfold more active than moxifloxacin against the different wild-type or mutant strains of S. pneumoniae, VGS, and E. faecalis, it was two- to fourfold less active than gemifloxacin. At four times the respective MIC for each strain, the bactericidal effect of garenoxacin, observed at 6 h for S. pneumoniae and at 24 h for S. oralis and E. faecalis, was not influenced by the presence of mutation either in the ParC or in both the ParC and GyrA QRDRs.


Antimicrobial Agents and Chemotherapy | 2004

Activities of Different Fluoroquinolones against Bacillus anthracis Mutants Selected In Vitro and Harboring Topoisomerase Mutations

Patrick Grohs; Isabelle Podglajen; Laurent Gutmann

ABSTRACT Three sets of mutants of Bacillus anthracis resistant to fluoroquinolones were selected on ciprofloxacin and moxifloxacin in a stepwise manner from a nalidixic acid-resistant but fluoroquinolone-susceptible plasmidless strain harboring a Ser85Leu GyrA mutation. A high level of resistance to fluoroquinolones could be obtained in four or five selection steps. In each case, ParC was the secondary target. However, in addition to the GyrA mutation, expression of high-level resistance required (i) in the first set of mutants, active drug efflux associated with a mutation in the QRDR of ParC; (ii) in the second set, two mutations in the QRDR of ParC associated with a mutation in GyrB; and (iii) in the third set, two QRDR mutations, one in ParC and one in GyrA. Interestingly, several selection steps occurred without obvious mutations in the QRDR of any topoisomerase, thereby implying the existence of other resistance mechanisms. Among the fluoroquinolones tested, garenoxacin showed the best activity.


Journal of Clinical Microbiology | 2013

Comparison of Five Media for Detection of Extended-Spectrum Beta-Lactamase by Use of the Wasp Instrument for Automated Specimen Processing

Patrick Grohs; B. Tillecovidin; A. Caumont-Prim; Etienne Carbonnelle; N. Day; Isabelle Podglajen; Laurent Gutmann

ABSTRACT Overall, 2,337 rectal screening samples (RSSs) were seeded by using the Wasp instrument for automated microbiological processing with five media for detection of extended-spectrum β-lactamase (ESBL): CHROMagar, ChromID, Brilliance, BD Drigalski, and HEGP media. Of 354 RSSs harboring ESBL-producing isolates, 89.3% were found to be positive on all media. Sensitivity and specificity ranged from 95.5 to 98.3% and from 57.9 to 72.3%, respectively. No medium was perfectly ESBL selective, and non-ESBL-producing strains were mainly Enterobacteriaceae overproducing AmpC β-lactamase and nonfermenting Gram-negative bacilli, mostly Pseudomonas aeruginosa.


Antimicrobial Agents and Chemotherapy | 2017

In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis

Patrick Grohs; Gary Taieb; Philippe Morand; Iheb Kaibi; Isabelle Podglajen; Marie Lavollay; Jean-Luc Mainardi; Fabrice Compain

ABSTRACT Ceftolozane-tazobactam was tested against 58 multidrug-resistant nonfermenting Gram-negative bacilli (35 Pseudomonas aeruginosa, 11 Achromobacter xylosoxydans, and 12 Stenotrophomonas maltophilia isolates) isolated from cystic fibrosis patients and was compared to ceftolozane alone, ceftazidime, meropenem, and piperacillin-tazobactam. Ceftolozane-tazobactam was the most active agent against P. aeruginosa but was inactive against A. xylosoxydans and S. maltophilia. In time-kill experiments, ceftolozane-tazobactam had complete bactericidal activity against 2/6 clinical isolates (33%).


Antimicrobial Agents and Chemotherapy | 2012

Molecular Basis for Different Levels of tet(M) Expression in Streptococcus pneumoniae Clinical Isolates

Patrick Grohs; Patrick Trieu-Cuot; Isabelle Podglajen; Sophie Grondin; Arnaud Firon; Claire Poyart; Emmanuelle Varon; Laurent Gutmann

ABSTRACT Seventy-four unrelated clinical isolates of Streptococcus pneumoniae harboring the tet(M) gene were studied. Seven strains with low tetracycline (Tc) MICs (0.25 to 0.5 μg/ml) were found to harbor truncated tet(M) alleles that were inactivated by different frameshift mutations. In contrast, five strains bore deletions in the tet(M) promoter region, among which four displayed increased Tc MICs (16 to 64 μg/ml). The same promoter mutations were detected in Tc-resistant mutants selected in vitro from various susceptible strains. Sequence analysis revealed that these deletions might impede the formation of the transcriptional attenuator located immediately upstream of tet(M). Expression in Enterococcus faecalis of a tet(M) reporter gene transcribed from these promoter mutants conferred a level of Tc resistance similar to that observed in the parental S. pneumoniae strains. These results show that different levels of Tc susceptibility found in clinical isolates of S. pneumoniae can be explained by frameshift mutations within tet(M) and by alterations of the upstream transcriptional attenuator.


Diagnostic Microbiology and Infectious Disease | 2011

Accuracy of MIC determination for Streptococcus pneumoniae using the Sirscan2000automatic MIC determination system

Patrick Grohs; Claire Janoir; Sophie Grondin; Sylvie Simon; Gaëlle Bonnet; Laura Henry; Laurent Gutmann; Emmanuelle Varon

The Sirscan2000automatic MIC determination (SIR-MD) system is a new system for MIC determination based on the automatic detection of growth of bacteria spotted onto agar medium using a camera scan. To evaluate its accuracy, 3608 Streptococcus pneumoniae clinical isolates yielding 18,165 MICs were tested in parallel with the SIR-MD and a standard interpretive antibiogram procedure. The overall percent agreement between the 2 methods within 1 log(2) dilution was 86.9%. After exclusion of the 11.8% noninterpretable results, errors in the deduction of susceptibilities were very major in 0.03%, major in 0.2%, and minor in 1.3%.

Collaboration


Dive into the Patrick Grohs's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fabrice Compain

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar

Jean-Luc Mainardi

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Claire Poyart

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marie Lavollay

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar

Philippe Morand

Paris Descartes University

View shared research outputs
Researchain Logo
Decentralizing Knowledge